Collegium Pharmaceutical Inc. (NASDAQ:COLL) is a stock that investors should take a bite out of.

After finishing at $28.23 in the prior trading day, Collegium Pharmaceutical Inc. (NASDAQ: COLL) closed at $28.58, up 1.24%. In other words, the price has increased by $+0.35 from its previous closing price. On the day, 569333 shares were traded. COLL stock price reached its highest trading level at $29.00 during the session, while it also had its lowest trading level at $27.43.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



Our goal is to gain a better understanding of COLL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.48. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 3.67 whereas as Long-Term Debt/Eq ratio is at 2.95.

Upgrades & Downgrades

On February 15, 2022, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $18 to $26.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 09 when Dreyer Scott sold 17,834 shares for $27.39 per share. The transaction valued at 488,554 led to the insider holds 102,798 shares of the business.

Heffernan Michael Thomas sold 19,815 shares of COLL for $470,253 on Dec 27. The Director now owns 28,023 shares after completing the transaction at $23.73 per share. On Dec 27, another insider, Ciaffoni Joseph, who serves as the President and CEO of the company, sold 2,204 shares for $23.75 each. As a result, the insider received 52,341 and left with 248,750 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69 while its Price-to-Book (P/B) ratio in mrq is 5.01.

Stock Price History:

Over the past 52 weeks, COLL has reached a high of $29.78, while it has fallen to a 52-week low of $14.04. The 50-Day Moving Average of the stock is 23.63, while the 200-Day Moving Average is calculated to be 18.86.

Shares Statistics:

The stock has traded on average 305.45K shares per day over the past 3-months and 403.28k shares per day over the last 10 days, according to various share statistics. A total of 34.57M shares are outstanding, with a floating share count of 33.15M. Shares short for COLL as of Oct 13, 2022 were 3.9M with a Short Ratio of 3.66M, compared to 3.69M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.42% and a Short% of Float of 15.92%.

Earnings Estimates

Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of $0.34 and a low estimate of -$0.65, while EPS last year was $0.22. The consensus estimate for the next quarter is -$0.07, with high estimates of $0.36 and low estimates of -$0.59.

Analysts are recommending an EPS of between $0.16 and -$1.78 for the fiscal current year, implying an average EPS of -$0.74. EPS for the following year is $1.82, with 4 analysts recommending between $2.88 and $1.25.

Revenue Estimates

6 analysts predict $124.45M in revenue for the current quarter. It ranges from a high estimate of $126.1M to a low estimate of $119.38M. As of the current estimate, Collegium Pharmaceutical Inc.’s year-ago sales were $84.89M, an estimated increase of 46.60% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $124.71M, an increase of 355.80% over than the figure of $46.60% in the same quarter last year. There is a high estimate of $128M for the next quarter, whereas the lowest estimate is $118.81M.

A total of 6 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $461M, while the lowest revenue estimate was $445.5M, resulting in an average revenue estimate of $456.29M. In the same quarter a year ago, actual revenue was $276.87M, up 64.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $553.83M in the next fiscal year. The high estimate is $568.9M and the low estimate is $541.4M. The average revenue growth estimate for next year is up 21.40% from the average revenue estimate for this year.